NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Wednesday as it traded at $29.78 compared with its previous 52-Week high of $29.73. Jazz is changing hands at $29.62 with 295,816 shares traded as of 10:36 a.m. ET. Average volume has been 699,300 shares over the past 30 days.

Jazz has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 47.3% year to date as of the close of trading on Tuesday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company has a P/E ratio of 34.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.

TheStreet Ratings rates Jazz as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including premium valuation and generally poor debt management. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix